Week of June 4, 2012: Catalent Expands Fill–Finish Capabilities; Siegfried Acquires Alliance Medical Products; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of June 4, 2012: Catalent Expands Fill–Finish Capabilities; Siegfried Acquires Alliance Medical Products; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Boehringer Ingelheim has established a new EUR 50-million+ ($62.2 million+) pilot-plant facility for the production of newly developed APIs in Biberach, Germany. The new technical center will have a useable area of approximately 2700-m2 (29062.56 ft2) and will host four manufacturing bays including four synthesis laboratories, which will handle the transfer of processes from laboratory to technical scale. The facility will have 15 chemical reactors with volumes of 100 to 300 liters, and is scheduled for completion in early 2014. Read More

Catalent Pharma Solutions has completed construction of its newly renovated 3300-ft2 aseptic fill–finish manufacturing facility at Research Triangle Park, North Carolina. The product-development group conducts preformulation, formulation development, process development, and manufacturing support in addition to offering analytical development and stability capabilities. The sterile clinical manufacturing suite will provide Class A manufacturing space containing a flexible aseptic vial-filling line capable of producing Phase I and Phase II clinical-trial materials. These fill–finish facilities are designed to comply with global GMP requirements. Read More

Eli Lilly has officially opened the Lilly China Research and Development Center (LCRDC) in Shanghai. The goal of the LCRDC is to discover diabetes medicines with mechanisms of action that can be tailored specifically for the Chinese population to delay the progression of the disease. Read More

Siegfried has acquired Alliance Medical Products (AMP), a sterile manufacturer, for $58 million. The purchase price specifies a contingent earn-out consideration subject to AMP meeting defined profitability goals for the fiscal year ended Dec. 31, 2013. Read More

Industry Briefs:

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here